Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Mesothelioma

Trial Information

An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

Official Title: A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma

Summary

Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.

Phase: Phase 2

Sponsor: Taxolog Inc.

Overall Contacts:

Harvey Pass, M.D.
(212)731-5414

Locations (2)

Country State City Zip Facility and Contact
United States Illinois Chicago 60637 University of Chicago
Sarah Mauro
773-834-3263
smauro@medicine.bsd.uchicago.edu

Hedy Kindler, M.D.
Principal Investigator
United States New York New York 10016 New York University Cancer Center
Harvey Pass, M.D.
212-731-5414
harvey.pass@med.nyu.edu

NCT ID:NCT00685204

Date Last Changed: May 22, 2008